EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Toward better cures for Mycobacterium abscessus lung disease

Véronique Dartois iD, Thomas Dick iD

Clinical Microbiology Reviews · 10.12.2024 · 37 (4)

DOI: 10.1128/cmr.00080-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 10.12.2024. Verfasst von Véronique Dartois und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Lung Diseases, Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The opportunistic pathogen Mycobacterium abscessus (Mab) causes fatal lung infections that bear similarities—and notable differences—with tuberculosis (TB) pulmonary disease. In contrast to TB, no antibiotic is formally approved to treat Mab disease, there is no reliable cure, and the discovery and development pipeline is incredibly thin. Here, we discuss the factors behind the unsatisfactory cure rates of Mab disease, namely intrinsic resistance and persistence of the pathogen, and the use of underperforming, often parenteral and toxic, repurposed drugs. We propose preclinical strategies to build injectable-free sterilizing and safe regimens: (i) prioritize oral bactericidal antibiotic classes, with an initial focus on approved agents or advanced clinical candidates to provide immediate options for desperate patients, (ii) test drug combinations early, (iii) optimize novel leads specifically for M. abscessus , and (iv) consider pharmacokinetic-pharmacodynamic targets at the site of disease, the lung lesions in which drug tolerant bacterial populations reside. Knowledge and tool gaps in the preclinical drug discovery process are identified, including validated mouse models and computational platforms to enable in vitro mouse-human translation. We briefly discuss recent advances in clinical development, the need for readouts and biomarkers that correlate with cure, and clinical trial concepts adapted to the uniqueness of Mab patient populations for new regimen development. In an era when most pharmaceutical firms have withdrawn from antimicrobial drug discovery, the breakthroughs needed to fill the regimen development pipeline will likely come from partnerships between academia, biotech, pharma, non-profit organizations, and governments, with incentives that reward cooperation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsLung DiseasesMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsHumansDrug Discovery

Stichwörter der Autor:innen

Mycobacterium abscessusdrug discovery and developmentinfectious diseasemultidrug regimens

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA.

ORCID-Profile: Véronique Dartois, Thomas Dick

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Dartois, V., & Dick, T. (2024). Toward better cures for Mycobacterium abscessus lung disease. Clinical Microbiology Reviews, 37(4). https://doi.org/10.1128/cmr.00080-23

Vancouver

Dartois V, Dick T. Toward better cures for Mycobacterium abscessus lung disease. Clinical Microbiology Reviews. 2024;37(4). doi:10.1128/cmr.00080-23

BibTeX
@article{Dartois2024,
  author = {Dartois, Véronique and Dick, Thomas},
  title = {Toward better cures for Mycobacterium abscessus lung disease},
  journal = {Clinical Microbiology Reviews},
  year = {2024},
  volume = {37},
  number = {4},
  doi = {10.1128/cmr.00080-23}
}
Kostenlos starten →